Cargando…
Influenza, PCV13, and PPSV23 Vaccination Rates Among Inflammatory Bowel Disease Patients With Additional Co-Morbidities as per CDC Recommendations
Background Inflammatory bowel disease (IBD) and its immunosuppressive therapy alter the body's immune response, predisposing patients to higher infection risk preventable with vaccination. The CDC recommends every adult receive the annual influenza vaccine and patients with certain comorbiditie...
Autores principales: | Jordan, Ariel, Mills, Krystal, Sobukonla, Timothy, Kelly, Alexander, Flood, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556142/ https://www.ncbi.nlm.nih.gov/pubmed/34729268 http://dx.doi.org/10.7759/cureus.18387 |
Ejemplares similares
-
Sequential Administration of PCV13 Followed by PPSV23 Results in a More Robust Immune Response in PPSV23-Naïve Adults Age 60–64 Years
por: Chilson, Erica, et al.
Publicado: (2017) -
Antibody responses after sequential vaccination with PCV13 and PPSV23 in kidney transplant recipients
por: Mülling, Nils, et al.
Publicado: (2023) -
1098 The Immunogenicity of PCV13 compared to PPSV23 in Immunocompetent Older Adults with Stable High Risk Conditions
por: Schmoele-Thoma, Beate, et al.
Publicado: (2014) -
The cost-effectiveness of using pneumococcal conjugate vaccine (PCV13) versus pneumococcal polysaccharide vaccine (PPSV23), in South African adults
por: Feldman, Charles, et al.
Publicado: (2020) -
Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Followed by the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) in Adults with and without Immunosuppressive Therapy
por: Garcia Garrido, Hannah M., et al.
Publicado: (2022)